Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669669 · ClinicalTrials.gov registry record · Phase 1
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00669669 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT00669669, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of temozolomide when given together with radiation therapy, carmustine, O6-benzylguanine, and patients' own stem cell (autologous) transplant in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Giving chemotherapy, such as temozolomide, carmustine, and O6-benzylguanine, and radiation therapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or plerixafor, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy.
Interventions
- BIOLOGICAL Filgrastim
- DRUG Carmustine
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- RADIATION 3-Dimensional Conformal Radiation Therapy
- PROCEDURE In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02-25 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669669
The ClinicalTrials.gov registry entry for NCT00669669 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Filgrastim is the first listed.
NCT00669669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669669 about?
NCT00669669 is a clinical study titled "O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas". This phase I/II trial studies the side effects and best dose of temozolomide when given together with radiation therapy, carmustine, O6-benzylguanine, and patients' own stem cell (autologous) transplant in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Giving chemothe...
What is the current status of trial NCT00669669?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-02-25. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT00669669?
The interventions under investigation include: Filgrastim (BIOLOGICAL), Carmustine (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), 3-Dimensional Conformal Radiation Therapy (RADIATION), In Vitro-Treated Peripheral Blood Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00669669?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.